Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: Analysis of the HIV-2 Belgium and Luxembourg database

• DOI: 10.1186/1471-2334-8-21
• Publication Date: 2008-02-27T19:13:50Z
• Authors: Jean Ruelle; François Roman; Anne-Thérèse Vand...; Christine Lambert; Katrien Fransen; Fedoua Echahidi; Denis Piérard; Chris Verhofstede; Kristel Van Laethem; Marie-Luce Delforge; Dolorès Vaira; Jean-Claude Schmit; Patrick Goubau
• Keywords: Resistance mutation; Medical microbiology; Protease inhibitor (pharmacology); HIV drug resistance

Abstract Background Guidelines established for the treatment of HIV-1 infection and genotype interpretation do not apply HIV-2. Data about antiretroviral (ARV) drug efficacy resistance mutations is scarce. Methods Clinical data HIV-2 infected patients in Belgium Luxembourg were collected effect ARV therapy on plasma viral load CD4 counts analysed. Viral RNA encoding protease (PR) reverse transcriptase (RT) from ARV-naïve treated sequenced. Results Sixty-five included this cohort. Twenty with 25 different combinations a total 34 regimens six months after start therapy, only one third achieved suppression. All these successful bar contained inhibitors (PIs). Mean gains group suppressors PI-containing respectively significantly higher than non-suppressors PI-sparing regimens. The most frequent selected under (compared to ROD) V71I, L90M I89V within PR. Within RT, they M184V, Q151M, V111I K65R. mutations, except K65R also found variable proportions patients. Conclusion Despite high rate failure, better virological immunological results analysis polymorphic positions specific during showed first time that transmission resistant viruses has occurred Luxembourg. heterogeneity reflects lack guidelines infection.